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Abstract: The omega-3 (n-3) long-chain polyunsaturated fatty acids (LC-PUFA), eicosapentaenoic
(EPA, 20:5n-3) and docosahexaenoic (DHA, 22:6n-3) acids, are well accepted as being essential
components of a healthy, balanced diet, having beneficial effects on development and in mitigating
a range of pathological conditions. However, their global supply from all the traditional sources
of these nutrients is insufficient to satisfy human nutritional requirements. For two decades there
has been considerable research carried out into all possible alternatives to the main sources of n-3
LC-PUFA, marine fish oil and fishmeal, driven largely by the aquaculture sector, as both the major
user and provider of EPA and DHA. In the last few years these efforts have focused increasingly
on the development of entirely new supplies of n-3 LC-PUFA produced de novo. Recently, this has
resulted in various new sources of EPA and/or DHA that are already available or likely to available
in the near future. In this short review, we briefly summaries the current gap between supply and
demand of EPA and DHA for human requirements, the role of aquaculture in providing n-3 LC-PUFA
to human consumers, the range of potential novel sources, and suggest how these new products
could be used effectively. We conclude that all the new sources have potentially important roles to
play in increasing the supply of n-3 LC-PUFA so that they are available more widely and in higher
concentrations providing more options and opportunities for human consumers to obtain sufficient
EPA and DHA to support more healthy, balanced diets.
Keywords: eicosapentaenoic acid; docosahexaenoic acid; novel sources; microalgae; oilseed crops;
genetic modification; aquaculture
1. Introduction
While the omega-3 (n-3) long-chain polyunsaturated fatty acids (LC-PUFA), eicosapentaenoic
(EPA, 20:5n-3) and docosahexaenoic (DHA, 22:6n-3) acids, can be produced endogenously by humans
and some fish species [1], their rate of biosynthesis is low and insufficient to meet physiological
demands [1,2] (Figure 1). Therefore, EPA and DHA are well accepted as being essential components of
a healthy, balanced diet, having beneficial effects on development especially of the neural system [3,4],
and in mitigating a number of pathological conditions [5–7]. However, what is not so well known
or appreciated is that these nutrients are in short supply [8]. There is simply not enough available
from all the traditional sources to satisfy human nutritional requirements, and aquaculture, both as
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a major user and provider of EPA and DHA, has been at the forefront in highlighting this gap between
demand and supply, and driving the omega-3 research agenda [2]. In recent years, this has led to
considerable academic and industry interest in developing entirely new supplies of n-3 LC-PUFA
and this has resulted in various products that are already in production or likely to go forward to
commercial production [9]. The present article briefly summarises the reasons behind the current gap
in supply and demand, the role of aquaculture, the new products likely to be available commercially
in the near future and longer term, and the opportunities and options these entirely novel sources of
n-3 LC-PUFA can provide in helping to promote balanced and healthy human diets.
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∆4 Fad enabling direct production of 22:6n-3 from 22:5n-3 has only been demonstrated in a few teleost
fish species and, therefore, DHA (22:6n-3) production from EPA (20:5n-3) in most fish species and
humans is only possible via the Sprecher shunt [1]. ∆4 Fad, ∆5 Fad and ∆6 Fad, fatty acyl desaturases;
DHA, docosahexaenoic acid; EPA, eicosapentaenoic acid; Elovl2, Elovl4 and Elovl5, fatty acid elongases.
Reproduced by permission from Tocher [2].
2. The Problem with the Available Supply of n-3 LC-PUFA
2.1. Gap between Supply and Demand
Our understanding of the beneficial effects of dietary EPA and DHA on human health has
been based largely on three main lines of evidence including epidemiological studies, randomized
controlled trials (RCT), and laboratory studies investigating biochemical and molecular mechanisms
that have provided considerable mechanistic support to the in vivo approaches [7,10,11]. Based on
all the evidence, many recommendations for EPA and DHA intake for a healthy human diet
have been produced by a large number of global and national health agencies and associations,
and government bodies [12,13]. The recommendations of over 50 organizations were compiled by the
Global Organization for EPA and DHA O ega 3 s [14] and, based on the most commonly recommended
dose for cardiac health (500 mg/person/day), the total demand for n-3 LC-PUFA can easily be
Nutrients 2019, 11, 89 3 of 20
calculated (500 mg/day × 365 days × 7 billion) to amount to over 1.27 million tonnes [2]. In contrast
to the considerable research into the benefits of dietary n-3 LC-PUFA, EPA and DHA, on human health,
and the amelioration of several pathological conditions [3–7,10–12], which has resulted in the plethora
of dietary recommendations [13,14], few studies on humans have even considered where all the n-3
LC-PUFA would come from if the dietary recommendations were followed by the human population.
However, three studies have attempted to calculate the difference between the demand to satisfy
human physiological requirements and the actual available supply of EPA and DHA [2,8,15]. While the
calculation of human requirements (demand) is relatively simple, calculating the available supply
of n-3 LC-PUFA is not, and requires various assumptions and estimates [see 2]. However, despite
this, all three studies came to the same conclusion, that the available supply of n-3 LC-PUFA was
insufficient to meet the demand to satisfy human requirements [2,8,15]. Indeed, in the journal issue,
which was dedicated to n-3 LC-PUFA and that contained the latest study to calculate n-3 LC-PUFA
supply [15], the editors chose to highlight the question “where will all the omega-3 fatty acids come
from” in the journal editorial [16]. Therefore, while the supply of n-3 LC-PUFA can be optimistically
estimated at just over 0.8 million tonnes indicating a shortfall of more than 0.4 million tonnes [2] or,
more pessimistically the deficit in supply has been calculated at over 1 million tonnes [15], the fact
that a significant gap exists is not in question irrespective of how it is calculated [8]. Furthermore,
the relentless increase in the global population translates into ever-growing demand.
2.2. Why Is There a Gap and What Impact Does It Have?
The calculations of supply in Tocher [2] highlight that the limitation in availability of EPA and
DHA is linked to their aquatic, predominantly marine, origin as oceans accounts for 96.5% of all
water on earth. While a very recent study has revealed that n-3 PUFA can be synthesised de novo in
some marine invertebrates [17], the vast majority is produced at the base of the marine food web in
marine microbes, including predominantly microalgae [18], whereas terrestrial plants do not produce
EPA or DHA [19]. Consequently, our supplies of n-3 LC-PUFA come from the oceans, the majority
(almost 90%) from capture fisheries, whether as food fish or via fish oil and fishmeal, with relatively
small additional amounts estimated from seafood by-products and recycling, unfed aquaculture
and traditional macroalgal sources [2]. Therefore, while other animal-derived foods can contribute
small amounts of n-3 LC-PUFA [20,21], access to, and consumption of, fish and seafood is the major
factor in determining how the diet of individuals and populations around the globe can satisfy n-3
LC-PUFA requirements. Indeed, a recent global survey of blood levels of EPA and DHA reported that
“populations living on coastal regions of countries, and populations that traditionally rely on hunting,
fishing and gathering for sustenance tended to have moderate to high blood levels of EPA+DHA” and
concluded that, while there was considerable variability in blood levels of EPA+DHA, “the very low to
low range of blood EPA+DHA for most of the world may increase global risk for chronic disease” [22].
In addition, public perceptions of fish, especially oily fish, leading to consumer resistance [21], as well
and various lifestyle choices [23,24] can also impact intake of n-3 LC-PUFA. In consequence, a very
large global study into consumption of dietary fats including 266 country-specific surveys, showed
that the global mean consumption of n-3 LC-PUFA was 163 mg/day [25]. While there was variation
in n-3 LC-PUFA consumption at both regional and national levels [25], the mean value was well
below the lowest recommended level for intake of around 250 mg/day [13,14]. It is in this context
that the fundamental, global lack of n-3 LC-PUFA to supply human needs for a healthy diet must
be considered.
3. The Roles of Aquaculture
Considering the origin of n-3 LC-PUFA in the marine environment it is therefore no surprise that
fish and seafood, traditionally from capture fisheries, have been the source of virtually all the EPA and
DHA in our diet. It is well documented that capture fisheries around the world are either at or beyond
their sustainable limits, plateauing at around 90 million tonnes per annum for the last decade or so
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and there is no prospect of this increasing in the future [26]. However, with an ever-growing global
population, demand for fish and seafood has constantly increased and aquaculture has increasingly
filled this demand with over half of all fish and seafood now being farmed [26]. However, there is
a problem. While fish vary in the amount of n-3 LC-PUFA they can contain, depending largely upon
whether oily or lean, they produce very little or none themselves, again dependent upon species.
Therefore, essentially all the EPA and DHA they contain is derived from their diet, the natural prey
organisms in wild-captured food fish or the manufactured feeds for farmed fish [2]. Consequently,
the only way to ensure farmed fish contained high levels of EPA and DHA was to include these fatty
acids in the feed and, until now, the only way to do this was to use large amounts of fish oil and
fishmeal, themselves derived from marine fisheries that are similarly finite and limiting [26]. This,
then, is the paradox. While aquaculture has increasingly become the major source of EPA and DHA
for the burgeoning human population, it has also, at the same time, become the greatest consumer of
the world’s available supply of EPA and DHA [27] and, consequently, the sector most proactive in
ensuring adequate future supplies [28].
The limitation in the supply of EPA and DHA has been an issue in aquaculture for over 20 years.
Initially the response was dictated by market forces that drove up prices of fish oil and fishmeal,
which naturally balanced demand to the existing supply. Thus, as aquaculture and the required
feed volumes expanded, the limited amount of fishmeal and fish oil was spread thinner and thinner
across the feeds, with fish oil being increasingly replaced by vegetable oils devoid of n-3 LC-PUFA,
but often containing high levels of n-6 PUFA [29]. While this strategy has been very successful in both
supporting the increasing demand for seafood and, at the same time, increasing the sustainability
of feeds with lower dependence upon marine ingredients [30], the consequently lower levels of EPA
and DHA in feeds was reflected in the farmed fish, impacting the nutritional quality of the farmed
products (Figure 2) [31,32].
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of replacing fish oil and fishmeal in feeds with vegetable oils and plant proteins [29], recent research
has focussed on finding more permanent solutions to the supply of EPA and DHA [2,9].
4. The Fundamental Solution
As EPA and DHA are naturally produced essentially only in the marine environment, that has
been an area of focus for efforts to find new sources. Such initiatives include other unexploited fisheries,
such as mesopelagic fish species, or fishing down the trophic levels, including zooplankton such as krill
or copepods. These options have been the subject of other reviews [2,38] and further detailed review
of these options is beyond the scope of this article. Suffice to say that, other than a relatively small
commercial krill fishery that provides limited amounts of krill meal and oil, other marine options have,
so far, not provided a solution to the problem of the supply of EPA and DHA [38]. Similarly, recycling
activities such as extracting oils from the by-products of wild capture fisheries and aquaculture is
already occurring, but is more an issue of efficiency in the use of existing, ultimately marine-derived,
sources and not new supplies of n-3 LC-PUFA [2]. Therefore, while obviously desirable, recycling
cannot be the solution to a problem that is only going to get bigger, i.e., the demand will constantly
increase due to population growth, as increasing efficiency by reducing waste can only ever maximise
the use of the existing, limited supplies.
All of the above represent further options for “harvesting” EPA and DHA, which is simply
applying a 19/20th century approach. It is clear that we require entirely new (de novo) supplies of
EPA and DHA and this, in turn, requires completely different approaches. In other words, we must
generate the EPA and DHA that we require, rather than simply recycle it. One approach has been to
apply modern technology to “farm” the marine organisms (i.e., the microalgae) that make the EPA and
DHA in the first place. While feasible, this option has required advances in industrial technologies to
enable scale-up of fermentation of heterotrophic species and/or bioreactor-like culture of phototrophic
species [39]. A second approach has been to use 21st century molecular technologies to utilise the
microalgal genes for the production of EPA and DHA in a well-established, efficient oil-producing
platform, oilseed crops [40,41]. Crops already produce almost 200 million tonnes of vegetable oils
annually with the only problem being that none of the plants can make the n-3 LC-PUFA, EPA and
DHA, that we need.
5. Alternative New Sources of EPA and DHA
Table 1 provides a brief summary overview of some potential new sources of EPA and DHA.
Some of these novel sources are already commercially available products while others are in
development and may well be available in the near future. Still others have been commercial products
but appear to be no longer available, and so there has been some volatility in this rapidly developing
and highly competitive market. The latter point also means that obtaining accurate, current data on
the different alternative new sources can be challenging and, therefore, some of the data in Table 1
may also be subject to change.
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Table 1. Summary of the origins and compositions of some potential new sources of EPA and DHA.
Composition a
Total n-3 LC-PUFA
Product Development Partners Source Type Lipid Content b EPA c DHA c % of TFA d % of Product Reference
AlgaPrime™ DHA Corbion (TerraVia/Bunge) e Microalgae Algal biomass 60 0 48 48 28 [42]
DHAgold™ DSM Nutritional Products Microalgae Algal biomass 49 1.0 44.4 45.8 22.5 [43]
DHA Natur™ ADM Animal Nutrition Microalgae Algal biomass 50–60 0.25 34 34.3 17.2–20.6 [44]
ForPlus™ Alltech Coppens f Microalgae Algal biomass 61 0.3 29 29.3 17.9 [45]
Nymega™ Heliae Development g Microalgae Algal biomass 65 ~0.1 20 ~31 21 [46]
Veramaris® Oil Veramaris h Microalgae Oil 100 ~16 ~34 ~54 ~54 [47]
Camelina sativa Rothamsted Research/UoS GM camelina Oil 100 20 0 24 24 [48]
Camelina sativa Rothamsted Research/UoS GM camelina Oil 100 9 11 28 28 [49]
Latitude™ BASF/Cargill GM canola Oil 100 7 1 12 12 [50]
Aquaterra™/Nutriterra™ i CSIRO/Nuseed/GRDC GM canola Oil 100 0.5 10 12 12 [51]
Yarrowia lipolyticaj DuPont GM yeast Yeast biomass ~50 ~50 0 50 25 [52]
a Compositional data were extracted or extrapolated from various sources and, in some cases, may differ in detail from final commercialised products. b Percentage of product; c Percentage
of total fatty acids (TFA); d Includes 20:4n-3 and 22:5n-3 (if any); e Initially developed by Terravia Holdings (formerly Solazyme) and to be commercially produced and marketed in joint
venture with Bunge. Acquired by Corbion after Terravia filed for bankruptcy with subsequent buyout of Bunge; f Initially developed by Alltech and, after acquiring Coppens International
feed company, was included in many of Alltech Coppens aquafeeds although this may not continue in the future with the closure of the microalgal facility in the USA; g Initially developed
by Heliae Development LLC and distributed in partnership with Syndel Laboratories Ltd.; h Initially developed by DSM and to be produced and marketed by Veramaris®, a 50:50 joint
venture with Evonik; i Oil from GM canola to be marketed as Aquaterra™ and Nutriterra™ for aquaculture and human consumption, respectively; j An oil from GM Y.lipolytica was once
marketed in capsule form as New Harvest™ EPA for human consumption. Compositional data extracted or extrapolated from the publications or publicly available materials cited in last
column. ADM, Archer Daniels Midland Company; CSIRO, Commonwealth Scientific and Industrial Research Organisation; GRDC, Grains Research and Development Corporation; UoS,
University of Stirling.
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The purpose of Table 1 is simply to give the reader an appreciation of the range of potential new
sources of EPA and DHA and how they differ in some key characteristics that may influence how
they are used. In this context, there are essentially only two main options for de novo production of
EPA and DHA, microalgae and genetically-modified oil producing organisms, particularly oilseed
crops. The microalgal sources are currently largely derived from the production of Thraustochytrid
species such as Schizochytrium and, occasionally, dinoflagellates like Crypthecodinium cohnii, that can
be produced heterotrophically by fermentation. This technology is scalable but limited mainly by
the capex required to produce very large biofermentor facilities [53]. A potential limitation with
Schizochytrium and Crypthecodinium ssp. is that they generally produce only DHA and not EPA and,
therefore, most of the microalgal products are only sources of DHA (Table 1).
However, the Veramaris® venture is utilising a Schizochytrium strain that produces both EPA
and DHA [54], and this is also being produced as an oil, which favours its inclusion in aquafeeds
as it can be simply included as a direct substitute/replacement for the oils (fish and vegetable oil
blends) currently used [55]. In contrast, the other microalgal products are all produced and marketed
as algal biomasses that are generally around 50% lipid, with the other 50% being accounted for by
varying proportions of protein, ash, and carbohydrate [56]. The precise nutrient composition of the
algal biomass will influence its use in feeds. This is also the case with the yeast Yarrowia lipolytica,
which was used as a biomass (approx. 50% lipid) when it was included in feeds for Atlantic salmon,
Salmo salar [57,58].
As oils, the GM oilseed products have, like Veramaris®, the advantage of being able to be used
in feeds as direct oil replacements. Production is also easily scalable as the infrastructure for the
cultivation, harvest, processing, distribution, marketing and utilisation of vegetable oils is highly
organised and well-established [59]. Depending upon the process of oil extraction it is possible that
added value may be obtained by the production of seed meals containing residual n-3 LC-PUFA,
which could be a commercial advantage supporting their use in animal feeds, within the normal limits
for canola/camelina meals based on their other nutritional (and antinutritional) properties [60–62].
The GM oilseeds also provide a variety of fatty acid compositions including an EPA-only oil or several
oils containing both EPA and DHA, from one containing high levels of both EPA + DHA, to oils that
are predominantly EPA or DHA with lower amounts of the other n-3 LC-PUFA [48,63,64]. This offers
the opportunity to utilise the oils in different ways.
6. Can these Products be Alternatives to Fish Oil in Aquaculture?
As fish oil has been our main source of EPA and DHA up until now, the above question may
appear the obvious one to ask, however, not without some further explanation. The use of the word
“alternatives” was deliberate as these products should be regarded as options to “supplement”,
and not simply “replace” existing fish oil supplies. This is not a matter of semantics, while fish
oil is undoubtedly finite on an annual/seasonal basis and, therefore, limited, it is not necessarily
an inherently “unsustainable” product. Like all fisheries globally, if the fisheries supplying fishmeal
and fish oil are managed effectively through regulation and control, and many are, there can be
a sustainable harvest of this valuable commodity and there is no sense in not utilising this [65]. This is
supported by the fact that the conversion ratio in the wild is around 10 kg of prey to 1 kg of food fish,
whereas aquaculture is far more efficient and productive [66]. Furthermore, harvesting fish higher in
the marine food web, such as cod, was shown to be far less efficient in providing marine nutrients for
human consumption compared to harvesting lower trophic level species such as capelin (on which cod
predate) and producing meal and oil for salmon production [67]. Thus, high trophic level predators
may require many times more marine resources than lower trophic level fish, such as menhaden or
anchovy used for reduction [65,68] and, hence, the importance of taking primary productivity into
account when comparing the eco-efficiency of reduction fishing with fishing of higher trophic species
for direct human consumption.
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Table 2 briefly summarises fish feeding trials using some potential new sources of EPA and DHA.
This is not intended to be a comprehensive review of all trials involving microalgal or GM sources
of n-3 LC-PUFA. Table 2 is restricted to the products listed in Table 1, or similar, related materials
tested as part of the development process, and limited to published and/or publicly available data.
Further details of studies on the use of microalgal products, largely biomasses, in on-growing feeds,
as opposed to larval feeds, was briefly reviewed recently [9]. In summary, there have been several trials
with a variety of algal biomasses in recent years with generally positive results, although there are two
caveats. Firstly, biomasses cannot directly replace the oil component of fish feeds due to the presence
of protein and, especially carbohydrate (largely non-starch polysaccharide, NSP) and this can limit the
total amount that can be incorporated into optimally balanced feeds without negative impacts.
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Table 2. Studies using the products listed in Table 1, or similar, related materials tested as part of the development process, as ingredients in feeds for fish a.
Product Species Replacing Inclusion Levels Reference
AlgaPrime™ DHA biomass b N/A
DHAgold™ biomass Cobia (Rachycentron canadum) FO and soybean oil 1.5, 2.2, 3.0 and 4.3% of diet c [69]
Atlantic salmon (Salmo salar) FO, FM and plant meals 5.5 and 11% of diet c [70]
Rainbow trout (Oncorhynchus mykiss) Corn oil and wheat flour 3, 6 and 9% of diet [71]
DHA Natur™ biomass Shrimp (Litopenaeus vannamei) FO and VO, soybean meal and wheat starch 1.3 and 5.0% of diet [72]
ForPlus™ biomass Drum (Totoaba macdonaldi) Corn starch 0.2 and 0.6% of diet [73]
Atlantic salmon FO, horse beans, maize gluten 1, 6 and 15% of diet [74]
Atlantic salmon FO and FM 2.5 and 5.0% of diet [45]
Shrimp (Litopenaeus vannamei) FO and wheat flour 0.6, 1.2, 1.8, 2.3 and 3.5% of diet [75]
Longfin yellowtail (Seriola rivoliana) FM 5% of diet [76]
Giant grouper (Epinephelus lanceolatus) FO, FM and squid 10, 15 and 18% of diet [77]
Red drum (Sciaenops ocellatus) FO, SPC and FM 1.3, 2.7, 4.0, 5.4, 6.7 and 9.9% of diet d [78]
Veramaris® oil Atlantic salmon FO 25, 50, 75 and 100% of FO e [55]
FO and FM 2–4 and 8–15% of diet [79]
Camelina sativa EPA oil Atlantic salmon FO and RO 100% of added oil [48,80]
Sea bream (Sparus aurata) FO and RO 100% of added oil [81]
Camelina sativa EPA+DHA oil Atlantic salmon FO and RO 100% of added oil [49,63,82]
Sea bream FO and RO 100% of added oil [81]
Latitude™ Atlantic salmon FO 100% of added FO f [83]
Aquaterra™ Atlantic salmon FO [84]
Yarrowia lipolytica biomass Atlantic salmon FM, wheat meal and RO 10–30% of diet [57,58]
a Limited to studies that have been published or reported publicly (e.g., open conferences etc.). Many more studies have likely been performed in “in-house” research and development
programmes. b N/A, None available. No published studies could be clearly identified as specifically testing AlgaPrime™ DHA; c AquaGrowGold®; d SP1 included along with Spirulina
meal at a ratio of ~1:4.2; e A second study replaced 25, 50 and 100% of EPA+DHA of FO; f Two diets with amount of GM Canola oil added to supply equal amounts of either EPA+DHA or
n-3 LC-PUFA (EPA+DHA+DPA). FM, fishmeal; FO, fish oil; RO, rapeseed oil; SPC, soy protein concentrate; VO, vegetable oils.
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Secondly, the biomasses only supply DHA, which has prompted considerable interest and
attention on DHA and EPA individually, and their relative value as essential fatty acids (EFA) [85].
While DHA is better retained than EPA, this probably does not reflect function, but rather is simply
due to the oxidation of DHA for energy being more complicated, requiring the involvement of
peroxisomes [2,86]. In addition, EPA and DHA differ in some fundamental antioxidant and membrane
effects [87] and, in this respect, DHA has specific key roles in neural (brain and eye) development and
function that EPA does not [88]. However, when it comes to metabolic and physiological control and
regulation, EPA and DHA both have important and different, albeit overlapping, roles. A detailed
examination and appreciation of their respective roles in controlling metabolism (e.g., as ligands for
transcription factors etc.) and also in inflammation, the key fundamental step in the response to
any injury or infection and the immune system, is outwith the scope of this review, and is covered
elsewhere [6,7,89,90]. Suffice to say that it is likely that an ideal new n-3 LC-PUFA source would supply
both EPA and DHA.
Peer-reviewed data on trials investigating the use of oils from genetically engineered oilseed crops
is fragmentary, being quite comprehensive in the case of GM Camelina, but more elusive in others.
An early study showed that oil derived from an GM oilseed crop could be used in aquafeeds without
any apparent negative effects related to “GM” [91]. While this was a stearidonic (18:4n-3)-containing oil
from genetically engineered soybean, and so not a direct source of EPA or DHA, it at least proved the
general concept. While information on trials involving oils derived from GM canola is sparse, recent
conference reports indicate that they have both been used successfully in trials generally replacing
the fish oil component in feeds for Atlantic salmon [83,84]. In contrast, studies investigating the
oils derived from genetically-engineered Camelina sativa, including both EPA-only and EPA+DHA
versions, have been extensively reported both in Atlantic salmon [48,49,63,80,82] and sea bream, Sparus
aurata [81]. In all these studies, the modified camelina oils have been used to replace both fish oil and
vegetable oil, showing that they can directly replace all the added oil in feeds without negative impacts
on fish growth or health. The most recent study showed that replacing both fish oil and rapeseed oil
with a camelina oil containing > 25% n-3 LC-PUFA doubled the EPA+DHA level in the flesh of the
salmon compared to fish fed the current commercial standard feed [49], suggesting that this oil could
restore levels in harvest-size salmon to those last seen more than a decade ago before the development
of sustainable feeds with high replacement of marine ingredients [31].
All the above confirms that the new sources of EPA and DHA have the potential to increase n-3
LC-PUFA levels in salmon and other farmed fish with no major negative impacts on fish growth,
feed efficiency and health. Thus, they can be real, practical alternatives to fish oil, not only in supplying
energy and satisfying EFA requirements of the fish, but also, most importantly, increasing levels of
EPA and/or DHA to pass on to human consumers ensuring farmed fish retain their position as key
components of a balanced, healthy diet.
7. Current Use in Commercial Aquafeeds and other Commercial Products
Algal biomasses are already being used in commercial aquafeeds. ForPlus™ is currently being
included in the formulation of a number of feeds produced by Alltech® Coppens including for
salmonids (e.g., the fishmeal and fish-oil-free “Neogreen” feed) and marine species, as well as
broodstock diets for freshwater species, although the exact amounts incorporated in the feeds are
unknown [92]. It is also unclear if this will continue in the future with the closure in January 2018 of
the Alltech US microalgae facility in Winchester, Kentucky [93]. The joint venture between Terravia
and Bunge resulted in a new large fermentation facility being established at a Bunge site in Brazil
processing sugarcane. This close association of algal production with the fermentation feedstock
increased the production volume of AlgaPrime™ DHA enabling an agreement for Terravia/Bunge
(now Corbion) to supply this product to the BioMar Group for inclusion in fish feed [94]. A similar
strategy to the above has been implemented by Veramaris® with a new fermentation facility being
built in Nebraska to use US corn syrup as fermentation feedstock, with initial production capacity
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upon commercial release in 2019 projected to meet up to 15% of the total current annual demand for
EPA and DHA by the global salmon aquaculture industry based on current inclusion levels [54].
The development of GM Y. lipolytica as a source of EPA by DuPont resulted in two commercial
products including New HarvestTM EPA, an encapsulated oil for direct human consumption,
and Verlasso® salmon, produced by AquaChile in 2016 using Y. lipolytica biomass in the feed [95].
However, Verlasso® salmon are now being produced using microalgae, rather than GM yeast biomass,
although the precise source and nature of the microalgal product is not known. While none of the
GM oilseed oils are yet fully commercialised both the groups involved in developing GM canola are
actively seeking approval for planting of the elite canola events they wish to commercialise through the
publication in the USA of the USDA Animal and Plant Health Inspection Service (APHIS) “Petition for
non-regulatory status” [50,51]. In addition, Nuseed have announced that two commercial products are
to be marketed including Aquaterra™ for aquaculture, and Nutriterra™ for human consumption [96].
Similarly, very recently Cargill announced the launch of Latitude™, their “a sustainable, plant-based
alternative source of omega-3 for fish feed applications” [97].
8. The Future
The above has demonstrated that the new sources can, to varying degrees depending upon
precise fatty acid composition, supply EPA and/or DHA and, therefore, supplement the existing
supplies of fish oil that will always be finite and limiting. But what exactly will be the future for all
these varied products? How will they be used and how will their different origins and compositions
affect their use? While this article has focused on the different biological and chemical characteristics
of the new sources, they also vary in the way their use could be impacted by socio-economic and
socio-political issues. While the microalgal products may have price implications associated with
the relatively high cost of production [53,93], GM-derived oils have issues associated with consumer
perception and acceptance in some countries, especially in the EU [98,99], as well as the hurdle of
regulatory approval. Furthermore, the gap between supply and demand was based on the calculated
‘physiological demand’, which is different to ‘commercial demand’. The latter currently includes
demand from the direct human consumption (capsule) market, as well as potential future demand
from other animal feed (poultry and pig) sectors, but the main driver will likely continue to be the
aquaculture sector. However, even within aquaculture, the use of the different new sources will not
only be dependent upon biological and technical factors of feed formulation and manufacture, but also
the overall aim and ambition of the sector, which is currently not clear and likely to be driven by
market forces dependent upon availability of supply and cost.
8.1. Use in Aquafeeds to Maintain Fish Growth and Health
The least ambitious aim would be to ensure aquafeeds satisfy the essential physiological
requirements of the fish itself, which minimally is the level required to prevent deficiency signs,
but optimally the level to ensure maximum growth and good health [2]. This would parallel the
current situation with essential amino acids (EAA). As certain EAA are deficient in many plant meals,
feeds are generally supplemented with small amounts of crystalline EAA (e.g., lysine and methionine)
to ensure requirements are met [60]. In the same way, high proportions of vegetable oils devoid of EPA
and DHA are used in more sustainable feed formulations and, while the feeds still satisfy minimum
requirements to prevent EFA deficiency, they may now be approaching sub-optimal for fish health.
This is exactly the situation faced by many human populations where instances of EFA deficiency
are rare or virtually unknown, but many/most have dietary levels of n-3 LC-PUFA and, especially
EPA and DHA, that are below dietary recommendations for optimal health [25]. In terms of EPA and
DHA content, microalgal oil (e.g., Veramaris®), is the closest EFA equivalent to crystalline EAA and
so it could be used in relatively small amounts to supplement current formulations with sufficient
EPA+DHA to ensure optimum fish health. Of course, while basic EFA requirement levels may be
known, the level of EPA+DHA required to ensure maximum growth and optimal health in fish fed
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modern, high performance (energy) feeds has arguably not been determined empirically for any fish
species [85]. Furthermore, a strategy focussing primarily on the requirements for fish health, and using
only relatively small amounts of the new EPA and DHA sources to replace some or all of the fish oil
currently used in feeds, would not tackle the gap between supply and demand for human consumers.
8.2. Use in Aquafeeds to Support Human Health
While the initial priority may be to supply sufficient dietary EPA and DHA to ensure fish health
and at least maintain current levels in farmed products [84], the ultimate goal should be to significantly
increase dietary levels so that farmed fish can deliver similar or higher levels of n-3 LC-PUFA than
wild fish. This will establish farmed fish as the best way by far for people to supplement their diets
with “omega-3” and confirm fish as key components of a healthy balanced diet.
Of course, ensuring that farmed fish can deliver high levels of EPA+DHA to human consumers
would require much higher levels to be included in the fish feed. This would mean using the new
sources not to replace some of the fish oil, but to replace the vegetable oil currently used in feeds.
How to implement this strategy would depend upon the fish species. Fish with low flesh fat content,
like many marine species, will require less dietary EPA+DHA to increase the proportions of these fatty
acids in the flesh, which is good, but they will not deliver the same ‘dose’ of EPA+DHA to human
consumers that an oily species like salmon can. However, for farmed salmon to deliver this high dose
it requires high levels of EPA+DHA in the feed. This will not be possible with microalgal biomasses
that cannot be incorporated into the feeds of salmonids, or marine fish, at the required high levels due
to the presence in the biomasses of substantial amounts of carbohydrates that, irrespective of the exact
type of carbohydrate, have very low nutritional value in carnivorous fish species with limited ability
to utilise dietary carbohydrate of any type [100]. However, this may not be exactly the case in lower
trophic level species with more omnivorous or herbivorous feeding habits [100].
8.3. Different Products, Different Niches?
The above sections discussed potential aims for using the new sources of EPA and DHA and how
different products could sit within these two main options. The following further explores the options
for using the new sources of EPA and DHA, specifically matching key characteristics of the varied
products with specific niche sectors within aquaculture.
As alluded to above, microalgal biomasses can be included in feeds for carnivorous species to
only a limited extent, at least partly due to the carbohydrate content that is relatively high, possibly
10–30% depending upon species albeit details of carbohydrate compositions are difficult to obtain for
any the biomasses or Schizochytrium/thraustochytrid species generally [101]. Most, if not all, of the
carbohydrate is assumed to be NSP, likely associated with the cell wall that, in addition to being
indigestible may further impact digestion of other nutrients, and so generally only 5–6% of algal
biomasses can be incorporated in feeds for salmon without compromising growth [56]. Fish species at
lower trophic levels, specifically herbivorous/omnivorous fish such as carps, tilapia and pangasius,
may have (slightly) better capacity to digest cell walls, if they have β-glucan components, due to the
possible presence in the intestine of enzyme activities (e.g., cellulases), whether of endogenous or,
more likely, microbial origin [100]. Therefore, if these species were more tolerant of algal biomasses,
and able to better digest biomass, increasing bioavailability of protein, lipid and minerals [102],
this could enable higher inclusion levels in feeds, and so could arguably be the niche market for these
products [103]. However, these species are generally not particularly high value fish, which makes the
economics of enhancing EPA + DHA levels in these species more difficult [93]. Similarly, they are not
high fat fish and so can only provide a limited ‘dose’ of EPA and DHA to consumers (Figure 3) [33].
However, these species are produced in huge tonnages and are important components of human diets
in many parts of the world, especially Asia and Africa, and so improvement of their nutritional value
through increased levels of DHA could benefit a very large number of people, many of whom have
low levels of n-3 LC-PUFA in blood [22].
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fatty acid co position closely reflects the fatty acid co position of the diet [104]. This is the ost
efficient ay of passing the high levels of EPA and DHA in these products on to human consumers via
farmed fish. With the microalgal oil, suitably high dietary levels of EPA+DHA would not necessarily
require the oil to be included at 100% of the added dietary oil. Due to the high proportion of n-3
LC-PUFA in the microalgal oil, near twice the level found in southern hemisphere fish oil, a 50:50 blend
with rapeseed oil could probably restore EPA+DHA levels in farmed salmon to that of a decade ago
before the development of sustainable feeds [31]. An alternative would be to just use one oil at 100% of
the added oil and this is precisely what the GM Camelina crop was designed to provide. The modified
camelina seed oil contains 20–25% n-3 LC-PUFA and, when used to replace both FO and rapeseed oil,
the level of n-3 LC-PUFA in flesh was doubled, suggesting that it could restore levels in harvest-size
fish to those of more than a decade ago, prior to the development of sustainable feeds [49,63].
In contrast, oils with lower proportions of total n-3 LC-PUFA may be less than ideal for oily
species like salmon in hich flesh fatty acid composition closely reflects dietary fatty acid compositions.
However, this may be less important in species that have lower levels of lipid in their flesh and where
a greater proportion of EPA and DHA in flesh lipid will be present in phospholipids rather than
in triacylglycerol [104]. Thus, the oils from other GM plants, which contain around 10–12% total
n-3 LC-PUFA could arguably be best sed in feeds for non-oily marine fish such as sea bream and
sea bass, as well as crustaceans (shrimp and prawns). These oils are also characterised by being
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either predominantly EPA (BASF/Cargill) or DHA (Nuseed/CSIRO) that, as discussed briefly above,
both have important but different metabolic and physiological roles. Assuming that some balance
between these two key n-3 LC-PUFA is desirable, albeit precisely what the optimum balance might be
is unknown, a blend of these two oils may be more beneficial than either individually, with a 1:1 blend
probably a reasonable starting point.
The above discussion simply aligns biochemical/nutrient composition data of the various new
sources of n-3 LC-PUFA with biological/physiological characteristics of aquaculture species and
suggests some potential matches. While these considerations could clearly aid the efficient utilisation
of EPA and DHA in the human food chain, it is acknowledged that market forces underpinned by
many other economic and socio- and geo-political factors will be equally important drivers for the
new n-3 LC-PUFA value chain.
8.4. Non-Aquaculture Uses
As long as there is a limited supply, aquaculture will remain the ideal delivery system for n-3
LC-PUFA to human consumers. As well as fish and seafood being well appreciated by consumers as
the traditional way to obtain these key nutrients, aquaculture production is generally far more efficient
than any terrestrial animal production [105]. Thus, highly efficient species such as Atlantic salmon [106]
feed conversion ratio (FCR) of around 1.1 to 1.2 in commercial production, compared to ~2 for poultry,
~3 for pigs, and > 6 for lamb and beef [105]. In addition, salmon show higher protein, energy and n-3
LC-PUFA retentions, and harvest and edible yields than terrestrial meat production [105]. However,
there can be further options if there were sufficient supplies of n-3 LC-PUFA to support other animal
feed uses as well as direct human consumption. Although not such an efficient way of utilising EPA and
DHA, supplementation of feeds for monogastric animals like pigs, and poultry (broilers and layers),
could increase n-3 LC-PUFA levels in pork [107], chicken [108] and eggs [109] as in the past when
feeds for these animals often contained fishmeal [110]. Supplementation of feeds for ruminants such as
cattle or sheep will only be sensible if good encapsulation methods were available to protect the fatty
acids in the rumen and prevent loss by biohydrogenation [111]. Supplementation of other food groups
with EPA and DHA is also a possible option especially after microencapsulation, and has been used
with milk, cheese, yoghurt, bread and juice [112,113]. The more widespread availability of EPA and
DHA in food may appear a long-term goal but one that has historically received attention in relation
to human dietary requirements [114]. In 2011, the Omega-3 summit recommended a “Dietary intake
of > 1000 mg of n-3 LC-PUFA was needed if consuming a western-type diet”, which was indicating
that current dietary recommendations [14] may be insufficient to ensure a balanced healthy diet [115].
This was further discussed at the recent 2018 Omega-3 Summit conference that held four key debate
sessions, “Strategies for Increased use of n-3 LC-PUFA for Improving Health”, “Matching Omega-3
Requirements with Omega-3 Supplies”, “Strategies for the Industry to Improve the Global Intake of
n-3 LC-PUFA” and “Strategies for Food and Food Ingredients Industry to Deliver n-3 LC-PUFA to
Consumers Worldwide in a Sustainable Way” [116].
9. Conclusions
The present review has highlighted the fundamental problem of inadequate supplies of n-3
LC-PUFA to satisfy human physiological requirements, briefly summarised the potential new sources
of these key nutrients, and provided some analysis of how these new products could be used effectively.
The overall conclusion is that all the new sources can have important roles to play in helping to support
healthy, balanced diets for people. The variety of new sources of EPA and DHA coming to market will
be highly beneficial as they can be targeted to different uses and, as they all find their niche markets,
this could help to draw down prices making their widespread use increasingly feasible.
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